Data from Clinical Trial Examining Sucampo Pharmaceuticals, Inc.'s Lubiprostone for the Treatment of Opioid-induced Bowel Dysfunction Presented at Digestive Disease Week Conference
BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.